Full history for every metric is available with a Kvantra account
PPD, Inc. (PPD)
Key financial summary
Financials in USD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 2,680 | 3,001 | 3,749 | 4,031 | 4,681 | 5,879 |
| Operating profit | $m | 509 | 654 | |||||
| Net profit | $m | - | 183 | 296 | 104 | 48 | 154 | 364 |
| EPS reported | $ | 0.44 | 1.01 | |||||
| Operating cashflow per share | $ | 0.72 | 0.72 | |||||
| Capex per share | $ | 0.47 | 0.47 | |||||
| FCF per share | $ | 0.25 | 0.25 | |||||
| Free cash flow | $m | 88 | 434 | |||||
| Net debt | $m | 3,684 | 3,070 | |||||
| Book value equity | $m | -747 | -424 | |||||
| Book value per share | $ | -2.15 | -1.18 | |||||
| Number of shares | m | 346.68 | 359.54 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 77.77 | - | |||||
| P/B LTM | x | -15.89 | -40.05 | |||||
| P/S LTM | x | 2.53 | 2.89 | |||||
| P/FCF LTM | x | 134.81 | 39.16 | |||||
| EV/EBITDA LTM | x | 22.74 | 21.83 | |||||
| EV/Sales LTM | x | 3.32 | 3.41 | |||||
| Earnings Yield LTM | % | 1.29% | 0.94% | |||||
| FCF Yield | % | 0.74% | 2.55% | |||||
| Quality | ||||||||
| ROE | % | -20.59% | -8.92% | |||||
| ROIC | % | 11.06% | 11.06% | |||||
| Operating margin | % | 10.88% | 10.88% | |||||
| Gross margin | % | 38.42% | 38.42% | |||||
| FCF/Sales | % | 1.88% | 1.88% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +214.29% | +400.50% | |||||
| Sales Growth YoY | % | +16.14% | +34.71% | |||||
| Net Income Growth YoY | % | +221.39% | +417.54% | |||||
| FCF Growth | % | -71.34% | +84.94% | |||||
| Operating Profit Growth | % | +21.73% | +43.07% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.02 | 0.10 | |||||
| Net Debt/EBITDA | x | 5.39 | 5.39 | |||||
| EBIT/Net interest | x | 2.35 | 2.35 | |||||
| Net debt/market cap | % | 31.05% | 18.06% | |||||
| Net debt/Equity | x | -4.93 | -7.23 | |||||
| Gross debt/equity | x | -5.96 | -10.40 | |||||
Company overview
PPD, Inc. delivers a full spectrum of drug development services internationally, primarily catering to the biopharmaceutical industry. The company structures its operations across two core divisions: Clinical Development Services and Laboratory Services. Under its Clinical Development arm, PPD provides a diverse range of support, including initial product strategy and advisory services, early-stage development, end-to-end management of clinical trials from Phase II through Phase IV, techniques for accelerated patient recruitment, assistance with pre- and post-market approval processes, and various medical communication solutions. Furthermore, its Laboratory Services segment encompasses specialized capabilities such as bioanalytical analysis, biomarker identification, vaccine science expertise, adherence to Good Manufacturing Practice (GMP) guidelines, and centralized laboratory testing. The firm's extensive client base reaches beyond pharmaceutical and biotechnology companies to include manufacturers of medical devices, governmental organizations, and other participants throughout the industry. PPD, Inc. was established in 1985 and maintains its corporate headquarters in Wilmington, North Carolina.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PPD, Inc. (PPD)
PPD, Inc. delivers a full spectrum of drug development services internationally, primarily catering to the biopharmaceutical industry. The company structures its operations across two core divisions: Clinical Development Services and Laboratory Services. Under its Clinical Development arm, PPD provides a diverse range of support, including initial product strategy and advisory services, early-stage development, end-to-end management of clinical trials from Phase II through Phase IV, techniques for accelerated patient recruitment, assistance with pre- and post-market approval processes, and various medical communication solutions. Furthermore, its Laboratory Services segment encompasses specialized capabilities such as bioanalytical analysis, biomarker identification, vaccine science expertise, adherence to Good Manufacturing Practice (GMP) guidelines, and centralized laboratory testing. The firm's extensive client base reaches beyond pharmaceutical and biotechnology companies to include manufacturers of medical devices, governmental organizations, and other participants throughout the industry. PPD, Inc. was established in 1985 and maintains its corporate headquarters in Wilmington, North Carolina.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free